Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis.

Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K.

Br J Psychiatry. 2008 Jun;192(6):406-11. doi: 10.1192/bjp.bp.107.037184. Review.

2.

[Schizophrenia, diabetes mellitus and antipsychotics].

Gury C.

Encephale. 2004 Jul-Aug;30(4):382-91. Review. French.

PMID:
15538314
3.

Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.

Citrome LL, Holt RI, Zachry WM, Clewell JD, Orth PA, Karagianis JL, Hoffmann VP.

Ann Pharmacother. 2007 Oct;41(10):1593-603. Epub 2007 Sep 4. Review.

PMID:
17785613
4.

Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?

Motlová L, Spaniel F, Höschl C, Balon R.

Ann Clin Psychiatry. 2007 Apr-Jun;19(2):133-43. Review.

PMID:
17612853
5.

Second generation antipsychotics for schizophrenia.

Feltus MS, Gardner DM.

Can J Clin Pharmacol. 1999 Winter;6(4):187-95. Review.

PMID:
10601752
6.

Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics.

Oliveira IR, Nunes PM, Coutinho DM, Sena EP.

Rev Bras Psiquiatr. 2009 Mar;31(1):52-6. Review.

7.

Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics.

Lublin H, Eberhard J, Levander S.

Int Clin Psychopharmacol. 2005 Jul;20(4):183-98. Review.

PMID:
15933479
8.

Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients.

Lacasse H, Perreault MM, Williamson DR.

Ann Pharmacother. 2006 Nov;40(11):1966-73. Epub 2006 Oct 17. Review.

PMID:
17047137
9.

Abnormal glucose metabolism in patients treated with antipsychotics.

Scheen AJ, De Hert MA.

Diabetes Metab. 2007 Jun;33(3):169-75. Epub 2007 Apr 6. Review.

10.
11.

Relationship of atypical antipsychotics with development of diabetes mellitus.

Citrome LL, Jaffe AB.

Ann Pharmacother. 2003 Dec;37(12):1849-57. Review.

PMID:
14632602
12.

Tardive dyskinesia and new antipsychotics.

Correll CU, Schenk EM.

Curr Opin Psychiatry. 2008 Mar;21(2):151-6. doi: 10.1097/YCO.0b013e3282f53132. Review.

PMID:
18332662
13.

Quality of life in the long-term treatment and the role of second-generation antipsychotics.

Mohr P.

Neuro Endocrinol Lett. 2007 Feb;28 Suppl 1:117-33. Review.

PMID:
17262004
14.

Management of schizophrenia with obesity, metabolic, and endocrinological disorders.

Monteleone P, Martiadis V, Maj M.

Psychiatr Clin North Am. 2009 Dec;32(4):775-94. doi: 10.1016/j.psc.2009.08.003. Review.

PMID:
19944883
15.

Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia.

Martin JL, Pérez V, Sacristán M, Rodríguez-Artalejo F, Martínez C, Alvarez E.

Eur Psychiatry. 2006 Jan;21(1):11-20. Epub 2005 Dec 27. Review.

PMID:
16380237
16.

Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems.

Hamann J, Leucht S, Kissling W.

Pharmacopsychiatry. 2003 Jan;36(1):18-26. Review.

PMID:
12649770
17.

Sexual dysfunction in schizophrenia: focus on recent evidence.

Baggaley M.

Hum Psychopharmacol. 2008 Apr;23(3):201-9. doi: 10.1002/hup.924. Review.

PMID:
18338766
18.

A review of atypical antipsychotic drugs versus conventional medication in schizophrenia.

Luft B, Taylor D.

Expert Opin Pharmacother. 2006 Sep;7(13):1739-48. Review.

PMID:
16925501
19.

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.

Edwards NC, Pesa J, Meletiche DM, Engelhart L, Thompson AK, Sherr J, Dirani R.

Curr Med Res Opin. 2008 Dec;24(12):3341-55. doi: 10.1185/03007990802490512 . Review.

PMID:
18954497
20.

Supplemental Content

Support Center